GENFIT S.A Current Ratio 2019-2022 | GNFT
GENFIT S.A current ratio from 2019 to 2022. Current ratio can be defined as a liquidity ratio that measures a company's ability to pay short-term obligations.
| GENFIT S.A Current Ratio Historical Data |
| Date |
Current Assets |
Current Liabilities |
Current Ratio |
| 2022-06-30 |
$0.24B |
$0.04B |
6.33 |
| 2021-12-31 |
$0.32B |
$0.07B |
4.27 |
| 2021-06-30 |
$0.15B |
$0.04B |
3.92 |
| 2020-12-31 |
$0.21B |
$0.04B |
5.95 |
| 2020-06-30 |
$0.26B |
$0.05B |
5.71 |
| 2019-12-31 |
$0.33B |
$0.05B |
6.66 |
| 2019-06-30 |
$0.34B |
$0.05B |
6.45 |
| 2018-12-31 |
$0.26B |
$0.05B |
5.56 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$0.208B |
$0.101B |
|
Genfit SA is a biopharmaceutical company. It focuses on the discovery and development of therapeutic and diagnostic solutions in metabolic and liver related diseases. The company's lead products include Elafibranor, Nitazoxanide and TGFTX1 which are in clinical stage. Genfit SA is based in Loos, France.
|
